Therapeutic guanidines
AssigneeWyeth
InventorsStanley M. Goldin, James B. Fischer, Andrew Gannett Knapp, N. Laxma Reddy, David Berlove, Graham J. Durant, Subbarao Katragadda, Lain-Yen Hu, Sharad Magar, Wenhong Fan, Elizabeth Yost, Juo Qing Guo
Life of this patent
Estimating the term…
Abstract
The present invention provides therapeutically useful substituted guanidines, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more of such guanidines.
Claims22
A method for treating a disorder of the nervous system in which the pathophysiology of the disorder involves excessive or inappropriate release of a neurotransmitter from neuronal cells, comprising administering to a mammal exhibiting symptoms of the disorder or susceptible to the disorder an effective amount of a compound of the following formula
- wherein R is substituted or unsubstituted carbocyclic aryl having at least about 5 ring atoms, substituted or unsubstituted aralkyl having at least about 5 ring atoms, or a substituted or unsubstituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to 8 ring members in each ring and from 1 to 3 hetero atoms;
- R1 is a substituted or unsubstituted carbocyclic aryl having at least about 5 ring atoms, or substituted or unsubstituted aralkyl having at least about 5 ring atoms, or a substituted or unsubstituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to 8 ring members in each ring and from 1 to 3 hetero atoms;
- and pharmaceutically acceptable salts thereof.
A method for treating a mammal suffering from or susceptible to a neurodegenerative disease, comprising administering to the mammal an effective amount of a compound of the following formula
- wherein R is substituted or unsubstituted carbocyclic aryl having at least about 5 ring atoms, substituted or unsubstituted aralkyl having at least about 5 ring atoms, or a substituted or unsubstituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to 8 ring members in each ring and from 1 to 3 hetero atoms;
- R1 is substituted or unsubstituted carbocyclic aryl having at least about 5 ring atoms, substituted or unsubstituted aralkyl having at least about 5 ring atoms, or a substituted or unsubstituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to 8 ring members in each ring and from 1 to 3 hetero atoms;
- and pharmaceutically acceptable salts thereof.
A method of treating a disease in which the pathophysiology of the disease involves inappropriate cellular secretion comprising administering to a mammal suffering from or susceptible to the disease an effective amount of a compound of the following formula
- wherein R is substituted or unsubstituted carbocyclic aryl having at least about 5 ring atoms, or substituted or unsubstituted aralkyl having at least about 5 ring atoms, or a substituted or unsubstituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to 8 ring member in each ring and from 1 to 3 hetero atoms;
- R1 is substituted or unsubstituted carbocyclic aryl having at least about 5 ring atoms, substituted or unsubstituted aralkyl having at least about 5 ring atoms, or a substituted or unsubstituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to 8 ring members in each ring and from 1 to 3 hetero atoms;
- and pharmaceutically acceptable salts thereof.
A method of modulating the release of excess endogenous neurotransmitters from a mammal comprising administering to the mammal an effective amount of a compound of the following formula
- wherein R is substituted or unsubstituted carbocyclic aryl having at least about 5 ring atoms, or substituted or unsubstituted aralkyl having at least about 5 ring atoms, or a substituted or unsubstituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to 8 ring members in each ring and from 1 to 3 hetero atoms;
- R1 is substituted or unsubstituted carbocyclic aryl having at least about 5 ring atoms, substituted or unsubstituted aralkyl having at least about 5 ring atoms, or a substituted or unsubstituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to 8 ring members in each ring and from 1 to 3 hetero atoms;
- and pharmaceutically acceptable salts thereof.
Dependencies are inferred from the claim text.